<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04642586</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/19/0055</org_study_id>
    <nct_id>NCT04642586</nct_id>
  </id_info>
  <brief_title>Detection of Subclinical Cerebral Suffering Related to Hypertension Using Multimodal MRI</brief_title>
  <acronym>SOUCHY</acronym>
  <official_title>Detection of Subclinical Cerebral Suffering Related to Hypertension Using Multimodal MRI (SOUCHY) Brain Changes Due to Hypertension: a Multimodal MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators propose here to study the brain consequences of hypertension in patients&#xD;
      without cognitive complaints and neurological signs. The evaluation of brain suffering&#xD;
      requires considering various possible brain damage. The team developed a multimodal MRI&#xD;
      approach capable of detecting and quantifying numerous indices (e.g. morphometric,&#xD;
      microstructural) to evaluate possible brain suffering. This project aims to identify&#xD;
      individually signs of cerebral suffering in hypertensive patients compared to a population of&#xD;
      normotensive volunteers, using advanced multiparametric MRI methods.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypertension is a risk factor for many brain pathologies, such as ischemic and hemorrhagic&#xD;
      neurodegenerative diseases or stroke. The literature seems to agree on the relationship&#xD;
      between hypertension and brain damage, and on the benefit of the management of hypertension&#xD;
      to prevent certain neurological pathologies. However, to our knowledge, no single study has&#xD;
      shown signs of subclinical brain damage in patients with hypertension. At present, no brain&#xD;
      MRI is recommended in these patients. In the present study, hypertensive and normotensive&#xD;
      patients will undergo a neurological exam, a neuropsychological exam, a biological exam and a&#xD;
      MRI exam to individually identify signs of cerebral suffering.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 7, 2021</start_date>
  <completion_date type="Anticipated">January 5, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 5, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of a cerebral zone with a z-score &gt; 1.96</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>the proportion of hypertensive patients who have at least one sign of cerebral suffering compared to the control group will be determined. For each MRI parameter, after coregistration, z score maps will be calculated for each hypertensive patient (individual vs normotensive group). The notion of cerebral suffering sign will be defined by the presence of a cerebral zone with a z-score greater than 1.96 (corresponding to a threshold of significance p &lt;.05).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>White matter hypersignals</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>FAZEKAS score estimating T2 hypersignals of the white matter,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbleeds</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>number and location of microbleeds,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gaps</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>number of gaps</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Correlation between MRI data and clinical scales</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>MRI parameters will be correlated with clinical and neuropsychological using Spearman 'rank correlation.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Hypertensive participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>diagnosed HTA within 5 years, treated or confirmed by Ambulatory Blood Pressure Measure;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normotensive participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>absence of HTA confirmed by Ambulatory Blood Pressure Measure</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>multimodal magnetic resonance imaging</intervention_name>
    <description>Brain MRI exam (without contrast injection)</description>
    <arm_group_label>Hypertensive participants</arm_group_label>
    <arm_group_label>Normotensive participants</arm_group_label>
    <other_name>MRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>blood test</intervention_name>
    <description>Blood test to evaluate cardiovascular risk factors (cholesterol, triglycerides, LDL and HDL-CT, serum creatinine, fasting glucose, serum potassium), .</description>
    <arm_group_label>Hypertensive participants</arm_group_label>
    <arm_group_label>Normotensive participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>neuropsychological assessment</intervention_name>
    <description>neuropsychological assessment</description>
    <arm_group_label>Hypertensive participants</arm_group_label>
    <arm_group_label>Normotensive participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female 35 to 50 y.o.;for patients: diagnosed HTA within 5 years, treated or&#xD;
             confirmed by Ambulatory Blood Pressure Measure;&#xD;
&#xD;
          -  For normotensive participants:Absence of HTA confirmed by Ambulatory Blood Pressure&#xD;
             Measure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known neurological history, stroke, symptomatic headache, long-term use of&#xD;
             neuroleptic, tricyclic, MAOI, anti-serotonergic antidepressant medications, diabetes&#xD;
             mellitus, treated dyslipidemia, body mass index greater than 30 kg / m, participants&#xD;
             who smoked or smoked more than 10 packs-year, MRI contraindication ;&#xD;
&#xD;
          -  For HTA patients only: Renal artery dysplasia responsible for hypertension, clinical&#xD;
             Cushing Syndrome.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Darcourt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean Darcourt, MD</last_name>
    <phone>+33561775620</phone>
    <phone_ext>33</phone_ext>
    <email>darcourt.j@chu-toulouse.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patrice Péran, PHD</last_name>
    <phone>05 62 74 61 96</phone>
    <phone_ext>33</phone_ext>
    <email>patrice.peran@inserm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean Darcourt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 6, 2020</study_first_submitted>
  <study_first_submitted_qc>November 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2020</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MRI, Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

